Enviar búsqueda
Cargar
Perinatal Outcome Following Third Trimester Exposure To Paroxetine
•
2 recomendaciones
•
516 vistas
B
Biblioteca Virtual
Seguir
Salud y medicina
Denunciar
Compartir
Denunciar
Compartir
1 de 4
Descargar ahora
Descargar para leer sin conexión
Recomendados
Lamotrigine In Breast Milk And Nursing Infants Determination Of Exposure
Lamotrigine In Breast Milk And Nursing Infants Determination Of Exposure
Biblioteca Virtual
Reproductive toxicology
Reproductive toxicology
Khadga Raj
Pooled Analysis Of Antidepressant Levels In Lactating Mothers, Breast Milk, A...
Pooled Analysis Of Antidepressant Levels In Lactating Mothers, Breast Milk, A...
Biblioteca Virtual
Reproductive toxicology
Reproductive toxicology
syeddastagir9
Reproductive toxicology studies ACCORDING TO OECD guidlines 422
Reproductive toxicology studies ACCORDING TO OECD guidlines 422
SONALPANDE5
Assignment on Reproductive toxicology studies
Assignment on Reproductive toxicology studies
Deepak Kumar
PPT On Female Reproductive Toxicology
PPT On Female Reproductive Toxicology
Naveen K L
Female reproductive toxicity studies acoording to SECHDULE Y AND ICH S5R3
Female reproductive toxicity studies acoording to SECHDULE Y AND ICH S5R3
SONALPANDE5
Más contenido relacionado
La actualidad más candente
Ich (s5 r2) The International Council for Harmonisationof Technical Requireme...
Ich (s5 r2) The International Council for Harmonisationof Technical Requireme...
AMIT KUMAR
Oecd for chronic toxicity
Oecd for chronic toxicity
pavanreddy292
Reproductive toxicology studies
Reproductive toxicology studies
kusuma khushi
The Transfer Of Drugs And Other Chemicals Into Human Milk
The Transfer Of Drugs And Other Chemicals Into Human Milk
Biblioteca Virtual
Pediatric Medication
Pediatric Medication
Vachhani Nirav
Reproductive toxicity studies
Reproductive toxicity studies
Loveinder Bhardwaj
PATTERN OF DRUG PRESCRIBING DURING PREGNANCY IN NEPALESE WOMEN
PATTERN OF DRUG PRESCRIBING DURING PREGNANCY IN NEPALESE WOMEN
Priyanka Shrestha
Animal toxicity studies
Animal toxicity studies
pathivada Haribabu
Act addiction and evolutionary process, common aspects in pharmaco toxicologi...
Act addiction and evolutionary process, common aspects in pharmaco toxicologi...
M. Luisetto Pharm.D.Spec. Pharmacology
Drugs in pregnancy&lactation
Drugs in pregnancy&lactation
WALID SARHAN
Drug uses in special physiology( pregnancy , lactation, infant , children, ge...
Drug uses in special physiology( pregnancy , lactation, infant , children, ge...
Akshil Mehta
Prescriber Update Sept 2014
Prescriber Update Sept 2014
Andrea Govender
Oecd acute,subacte, sub chronic dermal toxicity studies(402, 410, 411).
Oecd acute,subacte, sub chronic dermal toxicity studies(402, 410, 411).
helasri gummadi
Subacute toxicity testing as per oecd guidelines tulsi 407
Subacute toxicity testing as per oecd guidelines tulsi 407
Tulsi Gulabrao Patil
Reproductive Toxicology: History and State of Regulatory Science
Reproductive Toxicology: History and State of Regulatory Science
Joseph Holson
La actualidad más candente
(15)
Ich (s5 r2) The International Council for Harmonisationof Technical Requireme...
Ich (s5 r2) The International Council for Harmonisationof Technical Requireme...
Oecd for chronic toxicity
Oecd for chronic toxicity
Reproductive toxicology studies
Reproductive toxicology studies
The Transfer Of Drugs And Other Chemicals Into Human Milk
The Transfer Of Drugs And Other Chemicals Into Human Milk
Pediatric Medication
Pediatric Medication
Reproductive toxicity studies
Reproductive toxicity studies
PATTERN OF DRUG PRESCRIBING DURING PREGNANCY IN NEPALESE WOMEN
PATTERN OF DRUG PRESCRIBING DURING PREGNANCY IN NEPALESE WOMEN
Animal toxicity studies
Animal toxicity studies
Act addiction and evolutionary process, common aspects in pharmaco toxicologi...
Act addiction and evolutionary process, common aspects in pharmaco toxicologi...
Drugs in pregnancy&lactation
Drugs in pregnancy&lactation
Drug uses in special physiology( pregnancy , lactation, infant , children, ge...
Drug uses in special physiology( pregnancy , lactation, infant , children, ge...
Prescriber Update Sept 2014
Prescriber Update Sept 2014
Oecd acute,subacte, sub chronic dermal toxicity studies(402, 410, 411).
Oecd acute,subacte, sub chronic dermal toxicity studies(402, 410, 411).
Subacute toxicity testing as per oecd guidelines tulsi 407
Subacute toxicity testing as per oecd guidelines tulsi 407
Reproductive Toxicology: History and State of Regulatory Science
Reproductive Toxicology: History and State of Regulatory Science
Destacado
Forever Flowing:The Azure Legacy 2.5b
Forever Flowing:The Azure Legacy 2.5b
Geminiasp
6 My Home Modelo De InstalaçãO
6 My Home Modelo De InstalaçãO
Carlos Alberto Bonatto
Как перенос ИТ в облако ActiveCloud помогает в условиях кризиса. Примеры реш...
Как перенос ИТ в облако ActiveCloud помогает в условиях кризиса. Примеры реш...
Michael Kozloff
Financial Services Firms Claim the CX Advantage
Financial Services Firms Claim the CX Advantage
Lithium
Куда летят облака? Примеры внедрений, вопросы и прогнозы развития в России v.1.1
Куда летят облака? Примеры внедрений, вопросы и прогнозы развития в России v.1.1
Michael Kozloff
Chisholm Gallery/Leslie Shiels Canine Culture 2
Chisholm Gallery/Leslie Shiels Canine Culture 2
Chisholm Gallery, LLC ~ Polo + Sporting Art Specialits
Improving profit and utilazation in asset-intenensive industries
Improving profit and utilazation in asset-intenensive industries
IFS
Tammy Bality, Sculptures, presented by Chisholm Gallery, LLC
Tammy Bality, Sculptures, presented by Chisholm Gallery, LLC
Chisholm Gallery, LLC ~ Polo + Sporting Art Specialits
Rowan High School (test PP)
Rowan High School (test PP)
Geminiasp
ComunicaCity - la PA che comunica con il cittadino
ComunicaCity - la PA che comunica con il cittadino
ComunicaCity
Visual Arts Day 2014
Visual Arts Day 2014
artynelda
What Do the Asserts in a Unit Test Tell Us About Code Quality? (CSMR2013)
What Do the Asserts in a Unit Test Tell Us About Code Quality? (CSMR2013)
Maurício Aniche
Lenmana Island Travel Special
Lenmana Island Travel Special
Geminiasp
3. Public Limited Companies - Bus Man CFE Higher
3. Public Limited Companies - Bus Man CFE Higher
NBHS
Насколько велики Big Data?
Насколько велики Big Data?
Michael Kozloff
8. Public sector organisations (part 2) - Bus Man CFE Higher
8. Public sector organisations (part 2) - Bus Man CFE Higher
NBHS
Innovation Webinar Boost your business with enterprise apps
Innovation Webinar Boost your business with enterprise apps
IFS
Comunica city#sce2014
Comunica city#sce2014
ComunicaCity
Technology management in the age of the customer
Technology management in the age of the customer
Lithium
Legacyversery2
Legacyversery2
Geminiasp
Destacado
(20)
Forever Flowing:The Azure Legacy 2.5b
Forever Flowing:The Azure Legacy 2.5b
6 My Home Modelo De InstalaçãO
6 My Home Modelo De InstalaçãO
Как перенос ИТ в облако ActiveCloud помогает в условиях кризиса. Примеры реш...
Как перенос ИТ в облако ActiveCloud помогает в условиях кризиса. Примеры реш...
Financial Services Firms Claim the CX Advantage
Financial Services Firms Claim the CX Advantage
Куда летят облака? Примеры внедрений, вопросы и прогнозы развития в России v.1.1
Куда летят облака? Примеры внедрений, вопросы и прогнозы развития в России v.1.1
Chisholm Gallery/Leslie Shiels Canine Culture 2
Chisholm Gallery/Leslie Shiels Canine Culture 2
Improving profit and utilazation in asset-intenensive industries
Improving profit and utilazation in asset-intenensive industries
Tammy Bality, Sculptures, presented by Chisholm Gallery, LLC
Tammy Bality, Sculptures, presented by Chisholm Gallery, LLC
Rowan High School (test PP)
Rowan High School (test PP)
ComunicaCity - la PA che comunica con il cittadino
ComunicaCity - la PA che comunica con il cittadino
Visual Arts Day 2014
Visual Arts Day 2014
What Do the Asserts in a Unit Test Tell Us About Code Quality? (CSMR2013)
What Do the Asserts in a Unit Test Tell Us About Code Quality? (CSMR2013)
Lenmana Island Travel Special
Lenmana Island Travel Special
3. Public Limited Companies - Bus Man CFE Higher
3. Public Limited Companies - Bus Man CFE Higher
Насколько велики Big Data?
Насколько велики Big Data?
8. Public sector organisations (part 2) - Bus Man CFE Higher
8. Public sector organisations (part 2) - Bus Man CFE Higher
Innovation Webinar Boost your business with enterprise apps
Innovation Webinar Boost your business with enterprise apps
Comunica city#sce2014
Comunica city#sce2014
Technology management in the age of the customer
Technology management in the age of the customer
Legacyversery2
Legacyversery2
Similar a Perinatal Outcome Following Third Trimester Exposure To Paroxetine
Teratogenicity and the drugs causing it
Teratogenicity and the drugs causing it
TheDReamer3
Medical complications in pregnancy cmt april 2010
Medical complications in pregnancy cmt april 2010
NESSlideShare
Medical complications in pregnancy COMEP
Medical complications in pregnancy COMEP
NES
Broad spectrum antibiotics for preterm, prelabour rupture of fetal membranes-...
Broad spectrum antibiotics for preterm, prelabour rupture of fetal membranes-...
ASTRID JOHANNA LONDOÑO ARANGO
Broad spectrum antibiotics for preterm, prelabour rupture of fetal membranes-...
Broad spectrum antibiotics for preterm, prelabour rupture of fetal membranes-...
ASTRID JOHANNA LONDOÑO ARANGO
4 u1.0-b978-1-4160-4224-2..50022-3..docpdf
4 u1.0-b978-1-4160-4224-2..50022-3..docpdf
Loveis1able Khumpuangdee
Optimising maternal-fetal outcomes in preterm labour: a decision analysis
Optimising maternal-fetal outcomes in preterm labour: a decision analysis
Võ Tá Sơn
Drug use in pregnany
Drug use in pregnany
Dr B Naga Raju
Drugs in pregnancy
Drugs in pregnancy
Asha Reddy
Safety of Mebendazole Use During Lactation
Safety of Mebendazole Use During Lactation
mothersafe
Evidence of drug safety in pregnancy.pdf
Evidence of drug safety in pregnancy.pdf
Prof. Dr Pharmacology
2007 Tmih Artekin Trial Malaria In Cambodia
2007 Tmih Artekin Trial Malaria In Cambodia
wvdamme
Maternal Sertraline Treatment And Serotonin Transport In Breast Feeding Mothe...
Maternal Sertraline Treatment And Serotonin Transport In Breast Feeding Mothe...
Biblioteca Virtual
Acog 2011 acs for flm
Acog 2011 acs for flm
Asha Reddy
Unmasking the global abortion agenda
Unmasking the global abortion agenda
olopya
Repeat steroids when is it okay review 2012 ron wapner
Repeat steroids when is it okay review 2012 ron wapner
Asha Reddy
Drugs use in pregnancy
Drugs use in pregnancy
Vikas Sharma
Prescribing during pregnancy
Prescribing during pregnancy
Pravin Prasad
Teratogenecity & Safety of drugs in pregnancy
Teratogenecity & Safety of drugs in pregnancy
abhishekbharti51
Artículo que motivó la investigación
Artículo que motivó la investigación
Freddy Espinoza
Similar a Perinatal Outcome Following Third Trimester Exposure To Paroxetine
(20)
Teratogenicity and the drugs causing it
Teratogenicity and the drugs causing it
Medical complications in pregnancy cmt april 2010
Medical complications in pregnancy cmt april 2010
Medical complications in pregnancy COMEP
Medical complications in pregnancy COMEP
Broad spectrum antibiotics for preterm, prelabour rupture of fetal membranes-...
Broad spectrum antibiotics for preterm, prelabour rupture of fetal membranes-...
Broad spectrum antibiotics for preterm, prelabour rupture of fetal membranes-...
Broad spectrum antibiotics for preterm, prelabour rupture of fetal membranes-...
4 u1.0-b978-1-4160-4224-2..50022-3..docpdf
4 u1.0-b978-1-4160-4224-2..50022-3..docpdf
Optimising maternal-fetal outcomes in preterm labour: a decision analysis
Optimising maternal-fetal outcomes in preterm labour: a decision analysis
Drug use in pregnany
Drug use in pregnany
Drugs in pregnancy
Drugs in pregnancy
Safety of Mebendazole Use During Lactation
Safety of Mebendazole Use During Lactation
Evidence of drug safety in pregnancy.pdf
Evidence of drug safety in pregnancy.pdf
2007 Tmih Artekin Trial Malaria In Cambodia
2007 Tmih Artekin Trial Malaria In Cambodia
Maternal Sertraline Treatment And Serotonin Transport In Breast Feeding Mothe...
Maternal Sertraline Treatment And Serotonin Transport In Breast Feeding Mothe...
Acog 2011 acs for flm
Acog 2011 acs for flm
Unmasking the global abortion agenda
Unmasking the global abortion agenda
Repeat steroids when is it okay review 2012 ron wapner
Repeat steroids when is it okay review 2012 ron wapner
Drugs use in pregnancy
Drugs use in pregnancy
Prescribing during pregnancy
Prescribing during pregnancy
Teratogenecity & Safety of drugs in pregnancy
Teratogenecity & Safety of drugs in pregnancy
Artículo que motivó la investigación
Artículo que motivó la investigación
Más de Biblioteca Virtual
Aleitamento Materno Manual De OrientaçãO
Aleitamento Materno Manual De OrientaçãO
Biblioteca Virtual
Statistical Report Of The 2008 Iblce Examination
Statistical Report Of The 2008 Iblce Examination
Biblioteca Virtual
Lactation Management Self Study Modules Level I
Lactation Management Self Study Modules Level I
Biblioteca Virtual
AvaliaçãO Do Impacto De Um Programa De Puericultura Na PromoçãO Da Amamentaçã...
AvaliaçãO Do Impacto De Um Programa De Puericultura Na PromoçãO Da Amamentaçã...
Biblioteca Virtual
AnáLise Da Efetividade De Um Programa De Incentivo Ao Aleitamento Materno Exc...
AnáLise Da Efetividade De Um Programa De Incentivo Ao Aleitamento Materno Exc...
Biblioteca Virtual
Statistical Report Of The 2008 Iblce Examination
Statistical Report Of The 2008 Iblce Examination
Biblioteca Virtual
Uk Formula Marketing Practices
Uk Formula Marketing Practices
Biblioteca Virtual
Statistical Report Of The 2008 Iblce Examination
Statistical Report Of The 2008 Iblce Examination
Biblioteca Virtual
PromoçãO, ProtecçãO E Apoio. Apoio RepresentaçõEs Sociais Em Aleitamento Materno
PromoçãO, ProtecçãO E Apoio. Apoio RepresentaçõEs Sociais Em Aleitamento Materno
Biblioteca Virtual
O Ensino De Aleitamento Materno Na GraduaçãO Em Medicina Um Estudo De Caso
O Ensino De Aleitamento Materno Na GraduaçãO Em Medicina Um Estudo De Caso
Biblioteca Virtual
No Seio Da FamíLia AmamentaçãO E PromoçãO Da SaúDe No Programa De SaúDe Da ...
No Seio Da FamíLia AmamentaçãO E PromoçãO Da SaúDe No Programa De SaúDe Da ...
Biblioteca Virtual
Lactation Management Self Study Modules Level I
Lactation Management Self Study Modules Level I
Biblioteca Virtual
AnáLise Da Efetividade De Um Programa De Incentivo Ao Aleitamento Materno Exc...
AnáLise Da Efetividade De Um Programa De Incentivo Ao Aleitamento Materno Exc...
Biblioteca Virtual
AvaliaçãO Do Impacto De Um Programa De Puericultura Na PromoçãO Da Amamentaçã...
AvaliaçãO Do Impacto De Um Programa De Puericultura Na PromoçãO Da Amamentaçã...
Biblioteca Virtual
Iblce Regional Office In Europe Candidate Information Guide
Iblce Regional Office In Europe Candidate Information Guide
Biblioteca Virtual
A ImportâNcia Da AmamentaçãO Para A SaúDe Da Mulher Que Amamenta
A ImportâNcia Da AmamentaçãO Para A SaúDe Da Mulher Que Amamenta
Biblioteca Virtual
AmamentaçãO E Uso De AntiinflamatóRios NãO EsteróIdes Pela Nutriz InformaçõEs...
AmamentaçãO E Uso De AntiinflamatóRios NãO EsteróIdes Pela Nutriz InformaçõEs...
Biblioteca Virtual
Anatomofisiologia[1]
Anatomofisiologia[1]
Biblioteca Virtual
Contribution Of Environmental Factors To The Risk Of Male Infertility
Contribution Of Environmental Factors To The Risk Of Male Infertility
Biblioteca Virtual
Contraindications To Breastfeeding
Contraindications To Breastfeeding
Biblioteca Virtual
Más de Biblioteca Virtual
(20)
Aleitamento Materno Manual De OrientaçãO
Aleitamento Materno Manual De OrientaçãO
Statistical Report Of The 2008 Iblce Examination
Statistical Report Of The 2008 Iblce Examination
Lactation Management Self Study Modules Level I
Lactation Management Self Study Modules Level I
AvaliaçãO Do Impacto De Um Programa De Puericultura Na PromoçãO Da Amamentaçã...
AvaliaçãO Do Impacto De Um Programa De Puericultura Na PromoçãO Da Amamentaçã...
AnáLise Da Efetividade De Um Programa De Incentivo Ao Aleitamento Materno Exc...
AnáLise Da Efetividade De Um Programa De Incentivo Ao Aleitamento Materno Exc...
Statistical Report Of The 2008 Iblce Examination
Statistical Report Of The 2008 Iblce Examination
Uk Formula Marketing Practices
Uk Formula Marketing Practices
Statistical Report Of The 2008 Iblce Examination
Statistical Report Of The 2008 Iblce Examination
PromoçãO, ProtecçãO E Apoio. Apoio RepresentaçõEs Sociais Em Aleitamento Materno
PromoçãO, ProtecçãO E Apoio. Apoio RepresentaçõEs Sociais Em Aleitamento Materno
O Ensino De Aleitamento Materno Na GraduaçãO Em Medicina Um Estudo De Caso
O Ensino De Aleitamento Materno Na GraduaçãO Em Medicina Um Estudo De Caso
No Seio Da FamíLia AmamentaçãO E PromoçãO Da SaúDe No Programa De SaúDe Da ...
No Seio Da FamíLia AmamentaçãO E PromoçãO Da SaúDe No Programa De SaúDe Da ...
Lactation Management Self Study Modules Level I
Lactation Management Self Study Modules Level I
AnáLise Da Efetividade De Um Programa De Incentivo Ao Aleitamento Materno Exc...
AnáLise Da Efetividade De Um Programa De Incentivo Ao Aleitamento Materno Exc...
AvaliaçãO Do Impacto De Um Programa De Puericultura Na PromoçãO Da Amamentaçã...
AvaliaçãO Do Impacto De Um Programa De Puericultura Na PromoçãO Da Amamentaçã...
Iblce Regional Office In Europe Candidate Information Guide
Iblce Regional Office In Europe Candidate Information Guide
A ImportâNcia Da AmamentaçãO Para A SaúDe Da Mulher Que Amamenta
A ImportâNcia Da AmamentaçãO Para A SaúDe Da Mulher Que Amamenta
AmamentaçãO E Uso De AntiinflamatóRios NãO EsteróIdes Pela Nutriz InformaçõEs...
AmamentaçãO E Uso De AntiinflamatóRios NãO EsteróIdes Pela Nutriz InformaçõEs...
Anatomofisiologia[1]
Anatomofisiologia[1]
Contribution Of Environmental Factors To The Risk Of Male Infertility
Contribution Of Environmental Factors To The Risk Of Male Infertility
Contraindications To Breastfeeding
Contraindications To Breastfeeding
Último
pA2 value, Schild plot and pD2 values- applications in pharmacology
pA2 value, Schild plot and pD2 values- applications in pharmacology
DeepakDaniel9
Different drug regularity bodies in different countries.
Different drug regularity bodies in different countries.
kishan singh tomar
GOUT UPDATE AHMED YEHIA 2024, case based approach with application of the lat...
GOUT UPDATE AHMED YEHIA 2024, case based approach with application of the lat...
Internal medicine department, faculty of Medicine Beni-Suef University Egypt
DNA nucleotides Blast in NCBI and Phylogeny using MEGA Xi.pptx
DNA nucleotides Blast in NCBI and Phylogeny using MEGA Xi.pptx
MAsifAhmad
Unit I herbs as raw materials, biodynamic agriculture.ppt
Unit I herbs as raw materials, biodynamic agriculture.ppt
Pradnya Wadekar
SGK LEUKEMIA KINH DÒNG BẠCH CÂU HẠT HAY.pdf
SGK LEUKEMIA KINH DÒNG BẠCH CÂU HẠT HAY.pdf
HongBiThi1
Pharmacokinetic Models by Dr. Ram D. Bawankar.ppt
Pharmacokinetic Models by Dr. Ram D. Bawankar.ppt
RamDBawankar1
Biologic therapy ice breaking in rheumatology, Case based approach with appli...
Biologic therapy ice breaking in rheumatology, Case based approach with appli...
Internal medicine department, faculty of Medicine Beni-Suef University Egypt
American College of physicians ACP high value care recommendations in rheumat...
American College of physicians ACP high value care recommendations in rheumat...
Internal medicine department, faculty of Medicine Beni-Suef University Egypt
ANATOMICAL FAETURES OF BONES FOR NURSING STUDENTS .pptx
ANATOMICAL FAETURES OF BONES FOR NURSING STUDENTS .pptx
WINCY THIRUMURUGAN
Neurological history taking (2024) .
Neurological history taking (2024) .
Mohamed Rizk Khodair
SGK ĐIỆN GIẬT ĐHYHN RẤT LÀ HAY TUYỆT VỜI.pdf
SGK ĐIỆN GIẬT ĐHYHN RẤT LÀ HAY TUYỆT VỜI.pdf
HongBiThi1
Adenomyosis or Fibroid- making right diagnosis
Adenomyosis or Fibroid- making right diagnosis
Sujoy Dasgupta
PAIN/CLASSIFICATION AND MANAGEMENT OF PAIN.pdf
PAIN/CLASSIFICATION AND MANAGEMENT OF PAIN.pdf
Dolisha Warbi
Red Blood Cells_anemia & polycythemia.pdf
Red Blood Cells_anemia & polycythemia.pdf
MedicoseAcademics
Breast cancer -ONCO IN MEDICAL AND SURGICAL NURSING.pptx
Breast cancer -ONCO IN MEDICAL AND SURGICAL NURSING.pptx
Naveenkumar267201
How to master Steroid (glucocorticoids) prescription, different scenarios, ca...
How to master Steroid (glucocorticoids) prescription, different scenarios, ca...
Internal medicine department, faculty of Medicine Beni-Suef University Egypt
Mental health Team. Dr Senthil Thirusangu
Mental health Team. Dr Senthil Thirusangu
Medical University
Role of Soap based and synthetic or syndets bar
Role of Soap based and synthetic or syndets bar
mohitRahangdale
SGK RỐI LOẠN TOAN KIỀM ĐHYHN RẤT HAY VÀ ĐẶC SẮC.pdf
SGK RỐI LOẠN TOAN KIỀM ĐHYHN RẤT HAY VÀ ĐẶC SẮC.pdf
HongBiThi1
Último
(20)
pA2 value, Schild plot and pD2 values- applications in pharmacology
pA2 value, Schild plot and pD2 values- applications in pharmacology
Different drug regularity bodies in different countries.
Different drug regularity bodies in different countries.
GOUT UPDATE AHMED YEHIA 2024, case based approach with application of the lat...
GOUT UPDATE AHMED YEHIA 2024, case based approach with application of the lat...
DNA nucleotides Blast in NCBI and Phylogeny using MEGA Xi.pptx
DNA nucleotides Blast in NCBI and Phylogeny using MEGA Xi.pptx
Unit I herbs as raw materials, biodynamic agriculture.ppt
Unit I herbs as raw materials, biodynamic agriculture.ppt
SGK LEUKEMIA KINH DÒNG BẠCH CÂU HẠT HAY.pdf
SGK LEUKEMIA KINH DÒNG BẠCH CÂU HẠT HAY.pdf
Pharmacokinetic Models by Dr. Ram D. Bawankar.ppt
Pharmacokinetic Models by Dr. Ram D. Bawankar.ppt
Biologic therapy ice breaking in rheumatology, Case based approach with appli...
Biologic therapy ice breaking in rheumatology, Case based approach with appli...
American College of physicians ACP high value care recommendations in rheumat...
American College of physicians ACP high value care recommendations in rheumat...
ANATOMICAL FAETURES OF BONES FOR NURSING STUDENTS .pptx
ANATOMICAL FAETURES OF BONES FOR NURSING STUDENTS .pptx
Neurological history taking (2024) .
Neurological history taking (2024) .
SGK ĐIỆN GIẬT ĐHYHN RẤT LÀ HAY TUYỆT VỜI.pdf
SGK ĐIỆN GIẬT ĐHYHN RẤT LÀ HAY TUYỆT VỜI.pdf
Adenomyosis or Fibroid- making right diagnosis
Adenomyosis or Fibroid- making right diagnosis
PAIN/CLASSIFICATION AND MANAGEMENT OF PAIN.pdf
PAIN/CLASSIFICATION AND MANAGEMENT OF PAIN.pdf
Red Blood Cells_anemia & polycythemia.pdf
Red Blood Cells_anemia & polycythemia.pdf
Breast cancer -ONCO IN MEDICAL AND SURGICAL NURSING.pptx
Breast cancer -ONCO IN MEDICAL AND SURGICAL NURSING.pptx
How to master Steroid (glucocorticoids) prescription, different scenarios, ca...
How to master Steroid (glucocorticoids) prescription, different scenarios, ca...
Mental health Team. Dr Senthil Thirusangu
Mental health Team. Dr Senthil Thirusangu
Role of Soap based and synthetic or syndets bar
Role of Soap based and synthetic or syndets bar
SGK RỐI LOẠN TOAN KIỀM ĐHYHN RẤT HAY VÀ ĐẶC SẮC.pdf
SGK RỐI LOẠN TOAN KIỀM ĐHYHN RẤT HAY VÀ ĐẶC SẮC.pdf
Perinatal Outcome Following Third Trimester Exposure To Paroxetine
1.
ARTICLE Perinatal Outcome Following
Third Trimester Exposure to Paroxetine Adriana Moldovan Costei, MD; Eran Kozer, MD; Tommy Ho, MD, FRCPC; Shinya Ito, MD; Gideon Koren, MD, FRCPC Background: Paroxetine hydrochloride is commonly women using paroxetine during the first or second tri- used for maternal depression, panic disorder, and obses- mester and 27 women using nonteratogenic drugs were sive-compulsive disorder. The drug readily crosses the matched for maternal age, gravity, parity, social drug use, human placenta. Although it does not appear to in- and nonteratogenic drug use. crease teratogenic risk, there have been case reports of neonatal withdrawal. Symptoms were described soon af- Results: Of the 55 neonates exposed to paroxetine in ter birth and lasted up to 1 month. late gestation, 12 had complications necessitating inten- sive treatment and prolonged hospitalization. The most Objective: To investigate whether there is a clinically prevalent clinical picture was respiratory distress (n=9), important discontinuation syndrome in neonates ex- followed by hypoglycemia (n=2), and jaundice (n=1). posed to paroxetine in utero. The symptoms disappeared within 1 to 2 weeks. In the comparison group, only 3 infants experienced compli- Methods: Prospective, controlled cohort study. cations (P = .03). In logistic regression, only third- trimester exposure to paroxetine was associated with neo- Patients: Fifty-five pregnant women counseled pro- natal distress (odds ratio, 9.53; 95% confidence interval, spectively by the Motherisk program in Toronto, On- 1.14-79.3). tario, regarding third-trimester exposure to paroxetine and their infants were included in the study group. Preg- Conclusion: When used near term, paroxetine is asso- nant women who discontinued paroxetine before the third ciated with a high rate of neonatal complications, pos- trimester or those receiving other drugs known to cause sibly caused by its common discontinuation syndrome. withdrawal-type symptoms, such as opioids or benzodi- azepines, were excluded. A comparison group of 27 Arch Pediatr Adolesc Med. 2002;156:1129-1132 P AROXETINE HYDROCHLORIDE plasma ratio ranging from 0.056 to 1.3, and (Paxil; GlaxoSmithKline, the maximal daily dosage taken up by the Research Triangle Park, NC) infant is estimated at 0.34% of the mater- is commonly used for mater- nal dosage per kilogram of body weight.5-8 nal depression, panic disor- The objective of the present study was der, and obsessive-compulsive disorder in to compare the perinatal outcome of in- pregnant women. Although the drug does fants exposed in utero to paroxetine with not appear to cause major congenital mal- that of healthy controls and infants ex- formations,1 its perinatal safety when used posed to the drug only during the first and in late gestation has not been estab- second trimesters of pregnancy. lished. The drug readily crosses the hu- man placenta and has a mean elimina- METHODS tion half-life of 21 hours. There have been recently several neo- The Motherisk program provides counseling natal case reports of symptoms associ- for women and their health care providers on ated with maternal use of paroxetine,2-4 in- the risk or safety of drugs and chemicals dur- ing pregnancy and lactation. Presently, we are cluding irritability, jitteriness, constant From the Motherisk program, counseling as many as 200 patients a day. Be- Division of Clinical crying, shivering, eating or sleeping diffi- tween September 1996 and September 1999, Pharmacology/Toxicology, culties, gastrointestinal symptoms, and sei- we followed all pregnant women who called the Hospital for Sick Children, zures. These symptoms were described the Motherisk program about paroxetine ex- and the University of Toronto, soon after birth and lasted up to 1 month posure during the third trimester of preg- Toronto, Ontario. after birth. Paroxetine has a reported milk- nancy. These women were prospectively fol- (REPRINTED) ARCH PEDIATR ADOLESC MED/ VOL 156, NOV 2002 WWW.ARCHPEDIATRICS.COM 1129 Downloaded from www.archpediatrics.com on August 20, 2009 ©2002 American Medical Association. All rights reserved.
2.
between the study
and control groups (P .10) or those that Table 1. Maternal Characteristics* might confound the relationship between other variables and respiratory distress were included in a multivariate analysis. Vari- Paroxetine Hydrochloride ables were retained in the multivariate analysis if they met the Exposure in the significance level of P .05 or if they changed the point of es- Third Trimester timate of another variable by more than 10%. Comparison Cases Group† P RESULTS Characteristic (n = 55) (n = 54) Value Of 291 pregnant women who were counseled by the Maternal age, mean, y 32.9 32.4 .82 Gravidity Motherisk program about paroxetine use, 55 met the in- 1 19 (35) 18 (33) clusion criterion, being exposed to the drug during the .95 1 36 (65) 36 (67) third trimester. They used paroxetine for depression (31 Parity‡ women [56%]), anxiety (17 women [31%]), anxiety and 0 24 (44) 23 (43) depression (7 women [13%]), and panic attacks (5 women 1 22 (40) 19 (35) .94 [9%]) (some patients had more than 1 indication). The 2 7 (13) 9 (17) Social drug use daily dosage ranged from 10 mg to 60 mg (mean, 23 mg; Alcohol 4 (7) 9 (17) .12 median, 20 mg). Smoking 14 (26) 5 (9) .05 The maternal characteristics of the 2 groups are sum- marized in Table 1. The infants in the 2 comparison sub- *Data are presented as the number (percentage) of subjects unless groups did not differ in any characteristic and therefore otherwise indicated. were combined for the sake of comparison with the study †Comparison group included 27 women who used paroxetine only during the first and/or second trimesters and 27 women who used nonteratogenic group. drugs. Of the 55 infants exposed to paroxetine during the ‡Some women had parity higher than 2. third trimester of pregnancy, 12 experienced neonatal complications that necessitated prolonged hospitaliza- lowed up by telephone calls after delivery. The interview tions (Table 2). The most prevalent clinical picture was addressed the course of pregnancy, delivery, and the neonatal respiratory distress (n = 9), followed by hypoglycemia period, including malformations, developmental milestones, nu- (n=2) and jaundice (n=1). None of the infants had pneu- trition, etc. Interviewers did not make any suggestions about monia, cardiac malformation, respiratory distress syn- potential adverse outcomes. The protocol of the interview has drome, sepsis, or other causes of respiratory distress. In been previously outlined in detail.9 contrast, only 3 infants in the comparison group had neo- The inclusion criterion was exposure to paroxetine natal complications (2 infants with paroxetine expo- throughout the third trimester. Pregnant women who discon- sure in trimesters 1 and 2 had respiratory distress and tinued paroxetine before the third trimester or those receiving meconium aspiration, respectively; 1 of the nonterato- other drugs known to cause withdrawal-type symptoms, such genic controls had jaundice). The rate of neonatal com- as opioids, benzodiazepines, barbiturates, or heavy use of etha- nol, were excluded from the study. At the time of counseling, plications among neonates exposed to paroxetine in the we collected data on reproductive and medical history, de- third trimester (22%) was significantly higher than among tailed exposure data, and information on all other drugs used controls (6%) (P=.03). In the study group, there was a concomitantly. Details about cigarette, alcohol, and recre- significantly higher rate of prematurity (20% vs 3.7%; ational drug use were also collected. After delivery, partici- P =.02) (Table 3). pants were contacted again to record the pregnancy outcome In the third-trimester paroxetine exposure group, and neonatal complications, including withdrawal symptoms 36 women breastfed and continued taking paroxetine af- and breastfeeding. ter delivery. During breastfeeding, 8 women reported For each case, we chose a control mother-child pair from symptoms in their infants, including alertness (n=6), con- the same prospective cohort and matched them for maternal stipation (n=3), sleepiness (n=1), and irritability (n=1). age, gravity, parity, social drug use (alcohol and smoking), and nonteratogenic drug use (eg, acetaminophen, vitamins, and cal- In the comparison group, 44 babies were breastfed, and cium supplements). Two comparison groups were chosen. The none of the mothers reported adverse neonatal effects, first group included women counseled by Motherisk about ges- (P=.001). tational use of paroxetine only during the first and second tri- The following variables were initially included in a mesters (1-week to 6-months gestational age; median age, backward logistic stepwise regression model: prematu- 6 weeks). Daily dosage of paroxetine hydrochloride ranged from rity, maternal smoking, cesarean delivery, and exposure 10 mg to 40 mg, with a median of 20 mg. The second group to paroxetine in the third trimester (Table 4). The only included women counseled by Motherisk about first- factor retained in the model and found to be associated trimester exposure to nonteratogenic agents (eg, acetamino- with respiratory distress in the newborn was exposure phen or dental x-rays). to paroxetine in the third trimester (odds ratio, 9.53; 95% Data were analyzed with Statistical Product and Service Solutions software for Windows, version 10 (SPSS Inc, Chi- confidence interval, 1.14-79.30). cago, Ill). Descriptive statistics were used to summarize demo- graphic data. The 2 test was used to compare categorical vari- COMMENT ables, and the t test or Mann-Whitney test, as appropriate, was used for continuous variables. Backward stepwise logistic re- Paroxetine discontinuation symptoms have been re- gression was used to identify factors that could affect the rates ported at a rate of 0.3 per 1000 perscriptions.10 This may of respiratory distress. Variables found to differ significantly be partly due to the relatively high potency of parox- (REPRINTED) ARCH PEDIATR ADOLESC MED/ VOL 156, NOV 2002 WWW.ARCHPEDIATRICS.COM 1130 Downloaded from www.archpediatrics.com on August 20, 2009 ©2002 American Medical Association. All rights reserved.
3.
Table 2. Complications
Among Neonates Exposed to Paroxetine in the Third Trimester and the Comparison Groups* Patient No. Complication Relevant Details Paroxetine Hydrochloride Third Trimester Group (n = 55) 4 Bradycardia Term, septic workup was negative, echocardiogram, computed tomographic scan, 4-d hospitalization, no diagnosis 5 Respiratory distress Term, no sepsis, 1-wk hospitalization 9 Hypoglycemia Term, no sepsis 15 Respiratory distress, jaundice Preterm, intubation, phototherapy, 10-d hospitalization 20 Respiratory distress Term, placenta previa, bleeding, cesarean delivery, 2-wk hospitalization 21 Suckling problems Term, 2-wk hospitalization, no diagnosis 25 Respiratory distress Term, intubation 33 Respiratory distress, hypoglycemia Preterm, problems resolved in first few hours 35 Respiratory distress, tachycardia Preterm, 1 day in intensive care unit for respiratory distress 36 Respiratory distress Term 41 Respiratory distress Term 52 Respiratory distress Term Paroxetine First and Second Trimesters Group (n = 27) 18 Respiratory distress first few hours ... 29 Meconium aspiration, intubation ... Nonteratogenic Drugs Group (n = 27) 56 Jaundice ... *Ellipses indicate not applicable. Table 3. Pregnancy Outcome* Table 4. Univariate Analysis of the Association Between Risk Determinants for Respiratory Distress Paroxetine Hydrochloride in the Study Group Exposure in the Third Trimester Odds Ratio Variable (95% Confidence Interval) Comparison Cases Group† P Maternal smoking Variable (n = 55) (n = 54) Value No smoking 1.00 (Reference) Smoking 2.22 (0.52-9.52) Gestational age Maternal use of paroxetine hydrochloride Term 42 (76) 35 (65) .33 in the third trimester Preterm 11 (20) 2 (4) .02 Did not use paroxetine 1.00 (Reference) Postterm 2 (4) 17 (32) .001 Used paroxetine 10.35 (1.27-84.67) Birth weight, mean ±SD, g 3394 ± 650 3578 ± 464 .09 Gestational age, wk Sex 37 1.00 (Reference) Female 24 (44) 28 (52) .45 37 3.81 (0.85-17.13) Male 31 (56) 26 (48) Mode of delivery Major malformation 0 0 Vaginal 1.00 (Reference) Breastfed 36 (65) 44 (81) .85 Cesarean 0.92 (0.18-4.65) *Data are presented as the number (percentage) of subjects unless otherwise indicated. †Comparison group included 27 women who used paroxetine only during the and their conditions improved without further interven- first and/or second trimesters and 27 women who used nonteratogenic drugs. tion or emergence of other underlying diagnoses. It may be argued that the high rate of adverse neo- natal events, especially during breastfeeding, among in- etine at the serotonin uptake site. In adults, discontinu- fants exposed to paroxetine during the third trimester may, ation of selective serotonin reuptake inhibitors (SSRIs) at least in part, be associated with maternal psychiatric leads to nonspecific symptoms such as dizziness, pares- morbidity or disorders associated with it. However, half thesia, tremor, anxiety, nausea, and emesis, which typi- of our comparison group was composed of mothers who cally occur 2 days after the last dose and continue for an had similar conditions and who received the drug only average of 10 days.10 In a large British study, withdrawal during the first and second trimesters. Infants exposed reactions with paroxetine were 10-fold more common to the drug only during the first and second trimesters than with fluvoxamine maleate, which has a similarly short did not exhibit neonatal complications or higher rates half-life (fluvoxamine, 15 h; paroxetine, 17 h), and 15- of prematurity, as did those exposed in the third trimes- fold more common than with fluoxetine hydrochloride. ter. This strongly suggests that paroxetine exposure near In the present study, we detected a high rate of new- term may compromise fetal and neonatal health. The fact borns who developed neonatal complications at birth af- that the adverse events were brief and without other un- ter exposure to paroxetine in the third trimester. They derlying abnormalities further supports drug exposure all required intensive treatment for a short period of time, as the mechanism for the adverse effects. Logistic regres- (REPRINTED) ARCH PEDIATR ADOLESC MED/ VOL 156, NOV 2002 WWW.ARCHPEDIATRICS.COM 1131 Downloaded from www.archpediatrics.com on August 20, 2009 ©2002 American Medical Association. All rights reserved.
4.
What This Study
Adds Accepted for publication June 27, 2002. This study was supported in part by a grant from the Ca- nadian Institutes of Health, Ottawa, Ontario. Dr Kozer has a Paroxetine, an SSRI, is commonly used for depression, fellowship from the Research Training Center and Dr Koren panic disorder, and obsessive-compulsive disorder. Dis- holds the Research Leadership for Better Pharmacology Dur- continuation symptoms have been frequently de- ing Pregnancy and Lactation, Hospital for Sick Children, scribed in adults. Several case reports suggest that in- fants exposed in utero to paroxetine during the third Toronto, Ontario. Dr Ito is a scholar and Dr Koren is a senior trimester may have poor neonatal adaptation. The pres- scientist of the Canadian Institutes for Health Research. ent study is the first to compare the perinatal outcome Corresponding author: Gideon Koren, MD, FRCPC, Di- of women exposed to paroxetine during the third tri- vision of Clinical Pharmacology, Hospital for Sick Chil- mester of pregnancy with women who took paroxetine dren, 555 University Ave, Toronto, Ontario M5G 1X8, in early pregnancy and women who took nonterato- Canada (e-mail: gkoren@sickkids.ca). genic drugs. The incidence of complications (mainly res- piratory distress) was significantly higher in neonates exposed to paroxetine in late pregnancy. REFERENCES 1. Kulin NA, Pastuszak A, Sage SR, et al. Pregnancy outcome following maternal use of the new selective serotonin reuptake inhibitors. JAMA. 1998;279:609-610. 2. Nordeng H, Lindeman R, Perminov KV, Reikvam A. Neonatal withdrawal syn- sion analysis confirms that paroxetine exposure in the drome after in utero exposure to selective serotonin reuptake inhibitors. Acta Pae- third trimester, and not prematurity, maternal smok- diatr. 2001;90:288-291. ing, or other confounders, was associated with neonatal 3. Stiskal JA, Kulin N, Koren G, Ho T, Ito S. Neonatal paroxetine withdrawal syn- drome. Arch Dis Child Fetal Neonatal Ed. 2001;84:F134-F135. respiratory distress. 4. Dahl ML, Olhager E, Ahlner J. Paroxetine withdrawal syndrome in a neonate. Chambers et al11 reported poor neonatal adapta- Br J Psychiatry. 1997;171:391-392. tion in nearly one third of the neonates exposed to fluox- 5. Hale T. Medications and Mothers’ Milk. 9th ed. Amarillo, Tex: Pharmasoft Pub- etine. We have recently completed a study comparing lishing; 2000:514-515. 6. Spigset O, Carleborg L, Norstrom A, Sandlund M. Paroxetine level in breast milk pregnancy outcome and child development among chil- [letter]. J Clin Psychiatry. 1996;57:39. dren exposed to fluoxetine or tricyclic antidepressants 7. Begg EJ, Duffull SB, Saunders DA, et al. Paroxetine in human milk. Brit J Clin throughout gestation, and they did not exhibit an in- Pharmacol. 1999;48:142-147. crease in prenatal complications, compared with unex- 8. Stowe ZN, Cohen LS, Ritchie JC, et al. Paroxetine in human milk and nursing posed controls.12 Whether other SSRIs have neonatal tox- infants. Am J Psychiatry. 2000;157:185-189. 9. Koren G, ed. Maternal-Fetal Toxicology: A Clinician’s Guide. 3rd ed. New York, icity profiles similar to paroxetine’s remains to be explored. NY: Marcel Dekker Inc; 2001. The unexpected high rates of neonatal complications with 10. Price JS, Waller PC, Wood SM, MacKay AV. A comparison of the postmarketing paroxetine are biologically consistent with the high rate safety of 4 SSRI, including investigation of symptoms occurring on withdrawal. of discontinuation syndrome with this particular SSRI and Br J Clin Pharmacol. 1996;42:757-763. also with its being the most pharmacologically specific 11. Chambers CD, Johnson KA, Dick LM, Felix RJ, Jones KL. Birth outcomes in preg- nant women taking fluoxetine. N Engl J Med. 1996;335:1010-1015. of the SSRIs. More studies are needed to verify our ob- 12. Nulman I, Rovet J, Stewart DE, et al. Child development following exposure to servations and to better characterize pregnancy out- tricyclic antidepressants or fluoxetine throughout fetal life: a prospective con- comes and neonatal response. trolled study. Am J Psychiatry. In press. (REPRINTED) ARCH PEDIATR ADOLESC MED/ VOL 156, NOV 2002 WWW.ARCHPEDIATRICS.COM 1132 Downloaded from www.archpediatrics.com on August 20, 2009 ©2002 American Medical Association. All rights reserved.
Descargar ahora